Navigation Links
Clinical Trial Participation Today May Lead To Future Breakthroughs In Pancreatic Cancer, One Of The Nation's Deadliest Cancers
Date:1/6/2014

MANHATTAN BEACH, Calif., Jan. 6, 2014 /PRNewswire/ -- January marks the annual observance of National Pancreatic Cancer Clinical Trials Awareness Month.  The five year survival rate of pancreatic cancer is just six percent. In the effort to highlight the urgent need to improve the survival rate for this disease, the Pancreatic Cancer Action Network is educating the public about clinical trials and the critical role they play in making scientific progress.

(Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO)

In particular for pancreatic cancer, with few effective treatment options for patients, clinical trials are an extremely important part of the research process as scientists seek new, better treatments that will ultimately increase survival. Studies have determined that both a lack of awareness and low prioritization of clinical trials by physicians and patients facing cancer contribute to the low enrollment rates.

"Clinical trials are the way to make progress towards better treatments – participation today will shape the treatment landscape for the future," says Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. "In addition to being treated with new and innovative therapies, patients will be making a contribution to science by helping researchers learn more about the disease and help improve cancer care."

In 2013, nearly 45,000 Americans were diagnosed with pancreatic cancer and more than 38,000 died from the disease. A recent analysis reveals that pancreatic cancer is projected to move from the fourth to the second leading cause of cancer death in the United States by the year 2020.  Now more than ever, we need to change the course of pancreatic cancer.

"It is also essential for patients to know, that in all pancreatic cancer trials, patients always receive either the best standard treatment or the treatment being evaluated in the trial," adds Fleshman. "Thanks to clinical trial research and participation, significant advancements in the field of pancreatic cancer have been made. However, much still lies ahead."

To bring attention to the need for clinical trials and to increase enrollment, the organization's Patient and Liaison Services (PALS) program educates patients and caregivers about their options and the value of clinical trials. The program also conducts personalized searches using the organization's comprehensive, proprietary clinical trials database to determine potential eligibility. This database is the nation's leading resource for pancreatic cancer clinical trials.

To learn more about the Pancreatic Cancer Action Network, the PALS program and clinical trials, visit www.pancan.org/pals.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

Contact:
Anne Milo
Public Relations Manager
Pancreatic Cancer Action Network
Direct: 310-706-3357
Cell: 562-810-3016
Email: amilo@pancan.org

Video with caption: "January is National Pancreatic Cancer Clinical Trials Awareness Month, and you can help make progress in pancreatic cancer by spreading the word about the need for clinical research. With increased research and participation in clinical trials, we can learn faster and improve pancreatic cancer patient outcomes. To learn more about the Pancreatic Cancer Action Network, the PALS program and clinical trials, visit www.pancan.org." Video available at: http://www.youtube.com/watch?v=1Q33kPoZNKM


'/>"/>
SOURCE Pancreatic Cancer Action Network
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TauRx Expands Alzheimers Clinical Trials in the United States
2. ideaPoint, Inc. Announces Launch of Multi-Sponsor Portal Providing Researchers Opportunity to Request Access to Clinical Data from Five Global Study Sponsors
3. Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
4. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
5. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
6. Increased Dividends, Clinical Trial Results, Survey Results, and Updated Financial Guidance - Research Report on Aetna, Biogen, Eli Lilly, WellPoint, and Laboratory Corp. of America
7. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
8. Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
9. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
10. Array BioPharma Provides Clinical Update On ARRY-614 For Myelodysplastic Syndromes At The 2013 American Society Of Hematology Meeting
11. Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... The concept of rare diseases and the idea that a ... been taking shape in Europe since ... related to orphan medicinal products have been emerging at both ... individually. Many member states in the EU have led the ... products, the result of which took the shape of the ...
(Date:12/2/2016)... 1, 2016 Around the corners of world, ... each habitable land present over earth. Cancer has become ... in a life time this is because of the ... now. Given the steady increase in global cancer incidence ... spiraling healthcare costs of treatment, there is increasing interest ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... pharmaceutical organizations to build intelligent, connected applications, was named the best Sales Team ... , The winner announcement was made today by the Software & Information Industry ...
(Date:11/30/2016)... ... 30, 2016 , ... "I hate when the mixture of saliva and toothpaste ... an inventor from Bridgewater, N.J. "I thought that there had to be a way ... developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... tech functions and stylish design wanted by today’s consumers at an affordable price, ... Darin Philip says the new watch is “a game changer” when it comes ...
Breaking Medicine News(10 mins):